1
James Doherty
Clifton John Blankley, Annette Marian Doherty, James Marino Hamby, Robert Lee Panek, Mel Conrad Schroeder, Howard Daniel Hollis Showalter, Cleo Connolly: 6-Aryl pyrido�2,3-d! pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation. Charles W Ashbrook, March 31, 1998: US05733913 (64 worldwide citation)

6-Aryl pyrido�2,3-d!pyrimidines and naphthyridines are inhibitors of protein tyrosine kinase, and are thus useful in treating cellular proliferation mediated thereby. The compounds are especially useful in treating atherosclerosis, restenosis, psoriasis, as well as bacterial infections.


2
Stéphane De Lombaert
Bakthavatchalam Rajagopal, Caldwell Timothy M, Chenard Bertrand L, de, Lombaert Stéphane, Hodgetts Kevin J: Substituted quinolin-4-ylamine analogues. Neurogen Corporation, Bakthavatchalam Rajagopal, Caldwell Timothy M, Chenard Bertrand L, de, Lombaert Stéphane, Hodgetts Kevin J, ALEXANDER John B, January 27, 2005: WO/2005/007652 (5 worldwide citation)

Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion ...


3
Kevin Rodzinak
Vadim Y Dudkin, Mark E Fraley, Kenneth L Arrington, Mark E Layton, Alexander J Reif, Kevin J Rodzinak, Joseph E Pero: Positive allosteric modulators of MGLUR2. Merck Sharp & Dohme, Keith D MacMillan, John C Todaro, March 31, 2015: US08993779 (1 worldwide citation)

The present invention is directed to benzimidazolone derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involve ...


4
Toufike Kanouni
Qing Dong, Toufike Kanouni, Michael B Wallace: MAPK/ERK kinase inhibitors. Takeda Pharmaceutical Company, David M Stemerick, Mitchell R Brustein, September 20, 2011: US08022057 (1 worldwide citation)

Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using sa ...


5
Kevin Rodzinak
Philip E Sanderson, Mark E Layton, Kevin J Rodzinak: Inhibitors of akt activity. December 29, 2011: US20110319443-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


6
Toufike Kanouni
Qing Dong, Xianchang Gong, Stephen W Kaldor, Toufike Kanouni, Nicholas Scorah, Michael B Wallace, Feng Zhou: MAPK/ERK KINASE INHIBITORS. TAKEDA PHARMACEUTICAL COMPANY, TAKEDA SAN DIEGO, May 27, 2010: US20100130518-A1

Compounds of the following formula are provided for use with MEK (I): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of usin ...


7
Stéphane De Lombaert
Stéphane De Lombaert, Michel Jose Emmanuel: Chymase Inhibitors. Boehringer Ingelheim International, Michael P Morris, Boehringer Ingelheim Usa Corporation, February 4, 2010: US20100029637-A1

Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase.


8
Toufike Kanouni
MarK Adams, Qing Dong, Toufike Kanouni, Stephen W Kaldor, Nicholas Scorah, Michael B Wallace: Mapk/erk kinase inhibitors. Takeda Pharmaceutical Company, Takeda San Diego, May 14, 2009: US20090124595-A1

Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using sa ...


9
Kevin Rodzinak
Armstrong Donna J, Hu Essa H, Kelly Michael J Iii, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Rossi Michael A, Sanderson Philip E, Wang Jiabing: Inhibitors of akt activity. Merck &Amp Amp Co, February 21, 2008: KR1020077028878

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


10
Stéphane De Lombaert
Raymond F Horvath, Jennifer Tran, Stéphane De Lombaert, Kevin J Hodgetts, Philip A Carpino, David A Griffith: Certain alkylene diamine-substituted heterocycles. Neurogen, Pfizer, Sonia K Guterman, Lawson & Weitzen, July 11, 2006: US07074929

This invention relates to novel compounds, compositions, and methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. The novel compounds encompassed by the present invention are those of the formula II, IV, V, VII–IX and XI